Novel Therapies for Alopecia Areata: The Era of Rational Drug Development

December 2017 in “ The Journal of Allergy and Clinical Immunology ”

Etienne C.E. Wang, Zhijun Dai, Angela M. Christiano

alopecia areata corticosteroids contact immunotherapy TNF antagonists prostaglandin analogs minoxidil Abatacept TH2 antagonists TH17 antagonists JAK inhibitors Apremilast lipid-lowering agents Etanercept Alefacept efalizumab immune-related genes genome-wide association studies Rogaine

From the encyclopedia

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Minoxidil →

An essential vasodilator with some anti-androgenic effects

Studysummary This review discusses the evolution of alopecia areata treatments towards more targeted therapies and reports no new clinical results, emphasizing cooperation between clinicians and scientists in understanding the disease's pathophysiology. Our plain-language summary of this paper — not a Tressless recommendation.

The document from 2018 reviews the historical and contemporary treatments for alopecia areata (AA), an autoimmune condition affecting hair follicles. It notes that traditional treatments like corticosteroids and contact immunotherapy had mixed success and potential side effects. Repurposed drugs, such as TNF antagonists and prostaglandin analogs, showed disappointing results, while treatments for androgenetic alopecia like minoxidil were variably effective. The review emphasizes a shift towards targeted therapies, such as Abatacept, TH2 and TH17 antagonists, and JAK inhibitors, which are based on a deeper understanding of AA's pathophysiology. JAK inhibitors, in particular, have shown a 70% success rate in clinical trials, though relapses occur after treatment cessation. The document concludes that future AA treatments will likely be personalized, and further research into the immune mechanisms of AA is needed. Specific drugs like Apremilast and lipid-lowering agents have shown potential in early studies, while others like Etanercept, Alefacept, and efalizumab were ineffective. Genome-wide association studies have helped identify immune-related genes associated with AA, guiding the development of these novel, targeted therapies.

View this study on jacionline.org →

Discuss this study in the Community →

Research cited in this study

49 / 49 results

research Next Generation Human Skin Constructs as Advanced Tools for Drug Development

69 citations , June 2017 in “Experimental Biology and Medicine”

This review discusses the advancements and challenges in developing in vitro human skin models incorporating components like vasculature for drug testing and disease research, but reports no new clinical results.

research The Role of Micronutrients in Alopecia Areata: A Review

63 citations , May 2017 in “American Journal of Clinical Dermatology”

This review found that patients with alopecia areata may have lower levels of vitamin D, zinc, and folate, but conflicting evidence precludes definitive clinical recommendations for micronutrient supplementation.

research Treatment of Alopecia Areata With Tofacitinib

78 citations , March 2017 in “JAMA Dermatology”

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

research Two Cases of Alopecia Areata Treated with Ruxolitinib: A Discussion of Ideal Dosing and Laboratory Monitoring

25 citations , March 2017 in “International Journal of Dermatology”

In this case report, two women with chronic alopecia areata and acute alopecia universalis experienced sustained and near-complete hair regrowth after over a year of treatment with oral ruxolitinib, without significant side effects.

research Reversal of Alopecia Universalis by Tofacitinib: A Case Report

14 citations , November 2016 in “Annals of Internal Medicine”

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

research Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents

139 citations , November 2016 in “Journal of the American Academy of Dermatology”

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , November 2016 in “Journal of The American Academy of Dermatology”

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

research Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report

26 citations , October 2016 in “Case Reports in Dermatology”

In this study, tofacitinib treatment in a male patient with alopecia areata led to significant hair regrowth and improvement in nail dystrophy symptoms, restoring finger function within 10 months.

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations , September 2016 in “JCI insight”

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

196 citations , September 2016 in “JCI insight”

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

research Successful Treatment of Pediatric Alopecia Areata of the Scalp Using Topical Bimatoprost

14 citations , July 2016 in “Pediatric Dermatology”

In this report, a case of steroid-resistant multifocal alopecia areata was successfully treated with topical bimatoprost, suggesting it may be a promising alternative therapy.

$Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not Plaque Psoriasis with Tofacitinib in a Young Woman$

research Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not Plaque Psoriasis with Tofacitinib in a Young Woman

24 citations , June 2016 in “Acta dermato-venereologica”

In this case report, tofacitinib was associated with new hair growth on psoriasis lesions after three months of treatment.

research Genomewide Analysis of Copy Number Variants in Alopecia Areata in a Central European Cohort Reveals Association with MCHR2

29 citations , June 2016 in “Experimental Dermatology”

This study provides suggestive evidence that duplications in the MCHR2 gene may be involved in the pathogenesis of alopecia areata.

research Efficacy of Tofacitinib in Treatment of Alopecia Universalis in Two Patients

51 citations , June 2016 in “Journal of the European Academy of Dermatology and Venereology”

In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.

research ULBP3: A Marker for Alopecia Areata Incognita

15 citations , May 2016 in “Archives of Dermatological Research”

This study found significantly higher levels of the protein ULBP3 in patients with alopecia areata incognita compared to other hair loss conditions and healthy controls, suggesting ULBP3's potential as a diagnostic marker for AAI.

research Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers

70 citations , April 2016 in “Experimental Dermatology”

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.

research Transient Efficacy of Tofacitinib in Alopecia Areata Universalis

39 citations , April 2016 in “Case Reports in Dermatology”

This study observed initial hair regrowth in a businessman with alopecia areata universalis treated with tofacitinib, but the effect diminished, leading to renewed hair loss.

research Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata

157 citations , December 2015 in “Journal of the American Academy of Dermatology”

This case study reported significant but temporary hair regrowth and skin repigmentation in a patient with vitiligo and alopecia areata during treatment with oral ruxolitinib.

research Topical Ruxolitinib for the Treatment of Alopecia Universalis

96 citations , December 2015 in “JAMA dermatology”

This article discusses the potential of topical ruxolitinib as a treatment for alopecia universalis and acknowledges the need for alternatives to systemic JAK inhibitors due to the risk of serious side effects.

research Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated with Alopecia Universalis

41 citations , December 2015 in “JAMA Dermatology”

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

research Extensive Alopecia Areata Is Reversed by IL-12/IL-23p40 Cytokine Antagonism

68 citations , November 2015 in “The Journal of Allergy and Clinical Immunology”

In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.

research Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth

159 citations , October 2015 in “Science Advances”

This study observed that applying JAK-STAT pathway inhibitors to mouse and human skin led to rapid hair growth by inducing the anagen phase of hair follicles.

research Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing

176 citations , August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

This study identified a distinct cytokine activation signature in alopecia areata, involving TH2, TH1, IL-23, and IL-9/TH9 pathways, suggesting potential targeting strategies similar to those in psoriasis and atopic dermatitis.

research Evaluation of Serum Zinc Level in Patients With Newly Diagnosed and Resistant Alopecia Areata

52 citations , July 2015 in “International Journal of Dermatology”

This study found that patients with alopecia areata had significantly lower serum zinc levels, which correlated inversely with disease severity, duration, and resistance to therapies, suggesting zinc assessment as a marker of disease status.

research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

184 citations , February 2015 in “EBioMedicine”

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.

research Bimatoprost Versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study

36 citations , January 2015 in “Dermatology”

In this study, bimatoprost solution showed better results than corticosteroid in terms of rapidity, percentage of hair regrowth, and side effects for treating scalp alopecia areata.

research The PDE4 Inhibitor, Apremilast, Suppresses Experimentally Induced Alopecia Areata in Human Skin In Vivo

52 citations , December 2014 in “Journal of Dermatological Science”

Apremilast may help treat hair loss in alopecia areata.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis

185 citations , June 2014 in “Journal of Investigative Dermatology”

This case report describes complete hair regrowth in a patient with alopecia universalis and improved psoriasis after treatment with the oral Janus kinase inhibitor, tofacitinib.

How Effective Is Intralesional Injection of Triamcinolone Acetonide Compared with Topical Treatments in Inducing and Maintaining Hair Growth in Patients with Alopecia Areata? A Critically Appraised Topic

research How Effective Is Intralesional Injection of Triamcinolone Acetonide Compared with Topical Treatments in Inducing and Maintaining Hair Growth in Patients with Alopecia Areata? A Critically Appraised Topic

25 citations , February 2014 in “British journal of dermatology/British journal of dermatology, Supplement”

The authors concluded that intralesional triamcinolone acetonide may benefit patients with patch-type alopecia areata, but the evidence is limited due to small, bias-prone studies with variations in treatment protocols.

research Lack of Response to Laser Comb in Spontaneous and Graft-Induced Alopecia Areata in C3H/HeJ Mice

13 citations , January 2014 in “Journal of Investigative Dermatology”

The laser comb did not improve hair regrowth in mice with alopecia areata.

research Comparison of Zinc, Copper, and Iron Content in Hair and Serum in Alopecia Areata Patients with Normal Group

21 citations , January 2014 in “Dermatology Research and Practice”

This study found no significant difference in serum and hair levels of iron, zinc, and copper between female alopecia areata patients and healthy controls.

research The Genetic Architecture of Alopecia Areata

23 citations , December 2013 in “Journal of Investigative Dermatology Symposium Proceedings”

This study highlights rapid advances in alopecia areata treatment following the identification of genetic variants associated with increased disease risk, suggesting potential for precision medicine approaches.

research Effects of the Lexington LaserComb on Hair Regrowth in the C3H/HeJ Mouse Model of Alopecia Areata

81 citations , July 2011 in “Lasers in Medical Science”

This study found that using a low-level laser comb led to hair regrowth in a mouse model of alopecia areata, while sham-treated mice showed no hair regrowth.

research Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity

717 citations , June 2010 in “Nature”

This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.

research Type 1 Interferon Signature in the Scalp Lesions of Alopecia Areata

52 citations , March 2010 in “British Journal of Dermatology”

This study demonstrated the expression of type 1 interferon-related proteins in inflammatory lesions of alopecia areata, showing a distinct distribution pattern compared to cicatricial alopecia.

research Alefacept for Severe Alopecia Areata: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial

43 citations , November 2009 in “Archives of dermatology”

This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period.

research 308-nm Excimer Laser for the Treatment of Alopecia Areata in Children

79 citations , September 2009 in “Pediatric dermatology”

This study found that the 308-nm Excimer laser was effective and safe for treating patchy alopecia areata in children, with hair regrowth observed in 60% of treated scalp patches.

research Instilled Bimatoprost Ophthalmic Solution in Patients with Eyelash Alopecia Areata

30 citations , August 2009 in “Journal of the American Academy of Dermatology”

This study found that while bimatoprost was safe for 16 weeks, it was not effective for eyelash growth in patients with significant loss due to alopecia areata, though some with less loss experienced growth.

Lack of Efficacy of Topical Latanoprost and Bimatoprost Ophthalmic Solutions in Promoting Eyelash Growth in Patients with Alopecia Areata

research Lack of Efficacy of Topical Latanoprost and Bimatoprost Ophthalmic Solutions in Promoting Eyelash Growth in Patients with Alopecia Areata

55 citations , March 2009 in “Journal of The American Academy of Dermatology”

This study found that latanoprost and bimatoprost, when applied cutaneously to the eyelids, did not induce appreciable eyelash regrowth in patients with alopecia areata over 16 weeks.

research Serum Vitamin B12, Folate, Ferritin, and Iron Levels in Turkish Patients with Alopecia Areata

21 citations , January 2009 in “Indian journal of dermatology, venereology, and leprology”

Vitamin B12, folate, ferritin, and iron levels are not linked to alopecia areata.

research Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack

253 citations , December 2007 in “Journal of Investigative Dermatology”

This study suggests that human hair follicles may actively suppress natural killer cells, which contrasts with the observed defects in NK cell regulation in alopecia areata.

research Efficacy And Safety Of A New Clobetasol Propionate 0.05% Foam In Alopecia Areata: A Randomized, Double-Blind Placebo-Controlled Trial

114 citations , October 2006 in “Journal of the European Academy of Dermatology and Venereology”

In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.

research Influence of Prostaglandin F2α and Its Analogues on Hair Regrowth and Follicular Melanogenesis in a Murine Model

103 citations , April 2005 in “Experimental dermatology”

This study found that PGF2alpha analogues and PGE2 stimulated hair follicle activity in mice, with PGF2alpha analogues also linked to potential side effects like poliosis when used as eye treatments.

research Apoptosis Resistance in Peripheral Blood Lymphocytes of Alopecia Areata Patients

38 citations , September 2004 in “Journal of Autoimmunity”

Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.

research Clobetasol Propionate 0.05% Under Occlusion in the Treatment of Alopecia Totalis/Universalis

146 citations , July 2003 in “Journal of the American Academy of Dermatology”

In this study, clobetasol propionate 0.05% ointment was found to induce hair regrowth in 28.5% of patients with severe alopecia areata under occlusive conditions, though long-term benefit was limited to 17.8%.

Hypertrichosis and Increased Pigmentation of Eyelashes and Adjacent Hair in the Region of the Ipsilateral Eyelids of Patients Treated with Unilateral Topical Latanoprost

research Hypertrichosis and Increased Pigmentation of Eyelashes and Adjacent Hair in the Region of the Ipsilateral Eyelids of Patients Treated with Unilateral Topical Latanoprost

216 citations , October 1997 in “American Journal of Ophthalmology”

This study found that unilateral topical latanoprost use for glaucoma was associated with hypertrichosis and increased pigmentation of eyelashes in the treated eye compared to the untreated eye.

research Systemic Steroids With or Without 2% Topical Minoxidil in the Treatment of Alopecia Areata

101 citations , November 1992 in “Archives of Dermatology”

In this study, tapering prednisone followed by 2% topical minoxidil helped limit hair loss in some patients with alopecia areata, with 30% to 47% showing over 25% hair regrowth initially.

research A Comparison of Intralesional Triamcinolone Hexacetonide and Triamcinolone Acetonide in Alopecia Areata

75 citations , September 1971 in “British Journal of Dermatology”

This study found that both intralesional triamcinolone acetonide and triamcinolone hexacetonide promote continuous hair growth in alopecia areata, with effects lasting at least 9 months after a single injection.